Latest News
Get real-time updates on the latest news and developments in the pharmaceutical world. Stay informed about new drug launches, research findings, regulatory changes, and industry updates. Explore a wide range of topics and stay connected with the rapidly evolving world of pharma.
Magrolimab fails to improve survival in leukemia, Gilead halts trial
Another failure has occurred in Gilead Sciences’ $4.9 billion immuno-oncology wager. Following an ad hoc analysis of a phase 3 ...
Galecto slashes workforce, explores options after failed fibrosis trial
Boston-based biotech firm Galecto is facing a significant workforce reduction of 70%, affecting 29 employees, following the discontinuation of its ...
Roche and Ionis expand partnership with new RNA programs for Alzheimerās and Huntingtonās
Roche, in its quest to find effective treatments for Alzheimer’s diseases after the setbacks of gantenerumab, has reaffirmed its commitment ...
Croma Pharma faces backlash for lavish launch of new Botox rival
The UK’s regulatory body overseeing drug marketing has strongly criticized Croma Pharma for selecting a luxurious venue associated with “The ...
Merck KGaA’s MilliporeSigma Invests ā¬28 Million in 2 New mRNA Production Facilities
Merck KGaA’s MilliporeSigma has taken significant steps in its ā¬1 billion initiative to establish a global mRNA network, enhancing its ...
Gilead Sciences Proceeds with $247 Million Settlement in HIV Antitrust Case Following Trial Victory
Despite Gilead Sciences and Teva Pharmaceutical Industries emerging victorious in a high-stakes antitrust trial related to HIV drugs earlier this ...
Intercept Pharmaceuticals, After 2 FDA Setbacks and Restructuring Efforts, Finds a Buyer in Italy’s Alfasigma
Intercept Pharmaceuticals has faced substantial challenges over the past three years, particularly after the FDA rejected its attempts to bring ...
Roivantās IMVT-1402 lowers IgG without cholesterol or albumin issues, boosting CEO Glineās debut
Roivant CEO Matt Gline faced an immediate challenge in 2021 when he took the helm, discovering that Immunovant’s lead asset ...
AM-Pharma lays off staff and changes CEO after failed phase 3 trial of ilofotase alfa
After experiencing a setback in its phase 3 study for sepsis-associated acute kidney injury (SA-AKI), Dutch biotech company AM-Pharma is ...
UK signs deal with CSL Seqirus for UK-made pandemic flu vaccines
The most recent flu pandemic occurred in 2009, generating significant anticipation but ultimately causing relatively low impact. However, the level ...
J&J and IBM sued by patients over Janssen CarePath data breach
Johnson & Johnson, already grappling with talc product liability lawsuits, is now facing legal action from patients in relation to ...
Influential Pliant Persuades Investors, Propelling Stock Skyward with Promising Liver Disease Efficacy Data
Pliant Therapeutics has captured the attention of investors with compelling early clinical findings regarding its lead drug candidate’s potential to ...
Merckās antiviral pill Lagevrio may have triggered new COVID variants, study suggests
As concerns about the coronavirus continue to loom, the spotlight is once again on the most widely used oral antiviral ...
Takeda licenses AcuraStemās antisense drug for ALS targeting PIKFYVE
As scientific research continues to underscore the potential of targeting the PIKFYVE enzyme in the quest to combat amyotrophic lateral ...
Injectable hydrogel delivers HIV drug for six weeks in mice study
The landscape of HIV therapies has evolved significantly since the 1980s, when the FDA first approved the pioneering antiretroviral therapy ...
Ionisā olezarsen slashes triglycerides and pancreatitis in rare disease patients
Ionis Pharmaceuticals has achieved a significant milestone in its phase 3 clinical trial for lipid-lowering therapy, bringing the company closer ...
Roche denounces counterfeit Avastin that caused blindness in Pakistan
Following a distressing incident in which several diabetic patients were administered a counterfeit version of Roche’s Avastin, resulting in the ...
Pfizer resumes most of its drug production at tornado-damaged North Carolina plant
In the wake of a devastating summer tornado that struck Pfizer’s Rocky Mount injectables plant in North Carolina, significant strides ...
Pharma fails to impress mental health patient groups with R&D and pricing practices
The pharmaceutical industry continues to grapple with a less-than-stellar reputation among mental health patient groups, failing to shake off past ...
J&J launches campaign to raise awareness and support for multiple myeloma patients and caregivers
Johnson & Johnson’s multiple myeloma division is embarking on an initiative dubbed “Make It HAPPen,” aimed at bolstering support for ...
Novartis Eyes on First-Line Radiotherapy Role for Lutathera Following Triumph in Neuroendocrine Tumors Trial
Over half a decade since its inaugural FDA approval, Novartis is championing promising trial outcomes for Lutathera, positioning it as ...
Pfizer’s Abrysvo Secures CDC Endorsement for Infant Protection, Intensifying RSV Vaccine Competition
Despite GSKās Arexvy pioneering the respiratory syncytial virus (RSV) vaccine landscape earlier this summer, Pfizer has persistently challenged the competition ...
Leading Pharma Giants Support Lung Cancer Awareness Initiative for Hispanic and Latino Americans
Several prominent biopharma companies have united to champion a vital causeāraising awareness about lung cancer within the Hispanic and Latino ...
FDA Delay Coherus’ Approvals for PD-1 Inhibitor and Neulasta Biosimilar Injector
Coherus BioSciences has experienced a challenging journey in seeking FDA approval for its PD-1 inhibitor, toripalimab, developed in partnership with ...
Contamination Worries Prompt Scynexis to Recall Brexafemme, Putting Trials on Hold Following GSKās Manufacturing Review
In a surprising development, Scynexis is taking a precautionary step to withdraw its antifungal medication, ibrexafungerp, marketed as Brexafemme, from ...
Morphicās Shares Tumble as Updated Phase 2 Data Casts Shadows on Takedaās Entyvio Rival
Morphic Therapeutic has encountered a setback, as more comprehensive data from its much-anticipated EMERALD-1 trial unveiled uncertainties, causing its stock ...
AbbVie Withdraws from CD47 Arena, Ending Partnership with I-Mab
AbbVie has officially distanced itself from I-Mab, withdrawing from a once-promising collaboration focused on the anti-CD47 antibody lemzoparlimab, leaving I-Mab ...
Revivicor Breaks Ground in Xenotransplantation, Achieving Two Months of Stable Function in a Genetically Engineered Kidney
Revivicor, a division of United Therapeutics, has unveiled a groundbreaking advancement in organ manufacturing technology, using genetically engineered tissues from ...
VistaPharm Initiates Recall of Ulcer Medication Over Bacterial Contamination Concerns
The pharmaceutical landscape has witnessed several recalls initiated by the FDA due to drugs being contaminated with a spectrum of ...
Bayer and Hologic partner to promote contrast-enhanced mammography for breast cancer diagnosis
Bayer and Hologic have joined forces with the aim of providing enhanced breast cancer scans by combining Bayer’s imaging contrast ...
